Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash of -$10.47M in Q2 FY2026

Q2 FY2026 net change in cash was -$10.47M.

Context

  • Net change in cash amounted to 708.2% of revenue in FY2025.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$10.47M-124.2% QoQ
Last fiscal yearDec 2025
$9.56M-68.8% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-68.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
9.56M USD
Year-over-year change
-68.8%
1-year CAGR
-68.8%

Net Change in Cash vs competitors

How ATTO compares with its peers on the latest reported figures

  • ATTO's FY2025 net change in cash of $9.56M is the 9th largest of the 10 companies compared; the peer median is $26.92M.
  • Its year-over-year change of -68.8% is the 7th highest of 9, against a peer median of +79.9%.
  • Net change in cash amounts to 708.2% of revenue for ATTO, versus a peer median of 245.3%.
ATTO Competitors Peer median
Net Change in Cash for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$149.83M +233.4%—64.5%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$100.27M +131.4%+10.3%—
ALMSAlumis Inc. Common StockLTM Jun 2026$88.34M +2748.7%+2.1%1194.1%
ZURAZura Bio LimitedLTM Mar 2026$55.03M -31.9%——
EVMNEvommune, Inc.LTM Mar 2026$42.61M ——426.1%
CNTBConnect Biopharma Holdings LimitedFY2025$39.89M +45.4%-38.2%62323.4%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$26.92M +114.4%+69.8%—
QTTBQ32 Bio Inc.LTM Mar 2026$14.73M -70.6%—27.4%
ATTOAttovia Therapeutics, Inc.FY2025$9.56M -68.8%—708.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.7M -69.1%—20.3%
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ATTO) $26.92M+79.9%+6.2%245.3%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.